Green Lawrence J, Lain Edward, Prunty Thomas, Rhoades Robert
Dr. Green is with George Washington University School of Medicine in Washington, D.C.
Dr. Lain is with Sanova Dermatology in Austin, Texas.
J Clin Aesthet Dermatol. 2022 May;15(5):36-40.
The choice of vehicle is an important consideration in the treatment of acne and rosacea. Agents used to treat these common conditions may be limited by multiple factors, including poor stability during storage, limited residence time in the skin and follicular unit, and high potential for skin irritation. Novel drug delivery systems have been developed to address these problems, including microencapsulation, liposomal encapsulation, and the use of a variety of nanocarriers. New vehicle technologies for acne and rosacea treatments have appeared over the past 20 years and have somewhat improved stability, tolerability, and possibly efficacy. One of the latest vehicle technologies in acne and rosacea to enhance efficacy, stability, and tolerability is microencapsulation of benzoyl peroxide and tretinoin, which resulted in significant efficacy and good tolerability in patients with each of these two diseases. Other new vehicle technologies include a polymeric form of tretinoin and a microsphere product that combines tretinoin plus clindamycin. It is likely that there will be more reports of clinical success as experience with the rapidly evolving delivery technologies increases. This review summarizes drug delivery systems that have been developed with the aim of improving outcomes for patients being treated for either acne or rosacea. It also focuses, where possible, on formulations that have been evaluated in clinical studies.
载体的选择是治疗痤疮和酒渣鼻时的一个重要考量因素。用于治疗这些常见病症的药物可能会受到多种因素的限制,包括储存期间稳定性差、在皮肤和毛囊单位中的停留时间有限以及皮肤刺激的可能性高。已开发出新型药物递送系统来解决这些问题,包括微囊化、脂质体包封以及使用多种纳米载体。在过去20年中出现了用于痤疮和酒渣鼻治疗的新载体技术,并且在一定程度上提高了稳定性、耐受性以及可能的疗效。痤疮和酒渣鼻治疗中最新的提高疗效、稳定性和耐受性的载体技术之一是过氧化苯甲酰和维甲酸的微囊化,这在这两种疾病的患者中均产生了显著疗效和良好耐受性。其他新载体技术包括维甲酸的聚合物形式以及一种将维甲酸与克林霉素结合的微球产品。随着对快速发展的递送技术的经验增加,可能会有更多临床成功的报道。本综述总结了为改善痤疮或酒渣鼻患者的治疗效果而开发的药物递送系统。在可能的情况下,它还侧重于在临床研究中评估过的制剂。